Event Details
September 01, 2018
Description
Cronos and Ginkgo announced an agreement to produce cultured cannabinoids.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| Ginkgo Bioworks | organization | 4 | View Entity |
| NOS | organization | 40 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024837.jpg
Financial Research Report / Investment Analysis
• 1.41 MB
This document is page 21 of a Cowen Collaborative Insights report dated February 25, 2019, analyzing a strategic partnership between Cronos Group and Ginkgo Bioworks valued at $122MM. The text details the financial structure of the deal, including R&D funding and equity milestones for producing specific cannabinoids like THC and CBD. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, likely included in a larger cache of internal financial documents.
Event Metadata
Type
Unknown
Location
N/A
Significance Score
5/10
Participants
2
Source Documents
1
Extracted
2025-11-19 22:40
Additional Data
Source
HOUSE_OVERSIGHT_024837.jpg
Date String
2018-09-01
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event